New SKYTyphoid™ vaccine receives prequalification from World Health Organization

Global health leaders are aggressively improving access to new vaccines to combat the estimated 11 to 20 million typhoid fever cases and 120,000 deaths each year. SK bioscience’s SKYTyphoid™ typhoid conjugate vaccine has received prequalification from the World Health Organization, offering a safe and effective option for infants and young children. With significant outbreaks in sub-Saharan Africa and the first locally acquired case in Taiwan, the need for improved vaccines is evident.